Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails

Summary

BMS is approaching a clinical trial readout for a high-risk program that analysts believe could influence future mergers among mega-cap pharmaceutical companies. The company no longer has AstraZeneca as a safety net for potential negative outcomes.